

~~8~~
~~21.~~ The compound of claim 1 which is [11 β ,16 α (R,S)]-16,17-[cyclohexylmethylene)bis (oxy)]-11-hydroxy-21-(2-methyl-1-oxopropoxy)pregna-1,4-diene-3,20-dione.

9 ~~22.~~ The R-epimer of the compound of claim ~~21.~~⁸

10 ~~23.~~ The S-epimer of the compound of claim ~~21.~~⁸

11 ~~24.~~ A compound of claim 1 wherein each of is X₁ and X₂ is hydrogen.

12 ~~25.~~ A compound of claim 1 wherein each of X₁ and X₂ is fluorine.--

REMARKS

The amendments to the specification are entirely editorial in nature. Newly-presented claims 21 to 23 find antecedent support in Example VII. Claim 21 is directed to the title compound (designated by the *Chemical Abstract* name. The individual epimers of claims 22 and 23 find antecedent support in the first complete paragraph on page 22 of the specification. Claims 24 and 25 find antecedent support, e.g., in Table II (page 35 of the specification) and in original claim 1.


The Examiner's Answer (Paper No. 18) in the prosecution of SN 07/578,942 refused to consider evidence presented on Appellants' behalf because the data were not in Declaration form. On June 23, 1993, a Declaration (executed May 21, 1993) was filed on Appellants' behalf. The PTO is respectfully requested to enter

CALATAYUD et al.

that Declaration and to evaluate the patentability of the instantly-asserted claims in view of the evidence now of record in the prosecution of this application.

Respectfully submitted,

JACOBSON, PRICE, HOLMAN & STERN



Irwin M. Aisenberg
Reg. No. 19,007

400 Seventh Street, N.W.
Washington, D.C. 20004
Telephone: (202) 638-6666
Atty. Docket: 8125/P57770

D